Alberto Maino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alberto Maino has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Flora Peyvandi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
13 shared publications - Andrea Artoni
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
9 shared publications - Frits Richard Rosendaal
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
7 shared publications - Bob Siegerink
Department of Clinical Epidemiology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
6 shared publications - Ida Martinelli
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
6 shared publications - Maria Abbattista
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
5 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Human–LLM Dialogue Improves Diagnostic Accuracy in Emergency Care: Controlled Crossover Study (Preprint)
BACKGROUND Clinical decision-making in emergency medicine requires rapid, accurate diagnoses under uncertainty. Large language models (LLMs) have shown diagnostic potential, but evidence for their benefit in real physician workflows remains limited. OBJECTIVE This study evaluated whether MedSyn, a physician–LLM dialogue system, improves diagnostic accuracy in live emergency care workflows, and examined how benefit varies with case difficulty and physician expertise. METHODS Seven physicians (three senior internists, four residents) completed unassisted (baseline) and AI-assisted (interactive) sessions across 52 MIMIC-IV cases stratified by difficulty (Easy, Medium, Hard). Diagnostic performance was measured using automated fuzzy-matching metrics (any-match accuracy, exact-match accuracy, diagnosis-set F1) and blinded expert evaluation. Between-condition comparisons used paired bootstrap resampling (20,000 replicates, seed 42). RESULTS Interactive support significantly improved overall diagnostic accuracy: difficulty-standardised any-match accuracy improved by 0.156 (P < .001; d = 1.25). Residents showed the largest gains, with F1 improving by 0.138 (P < .001; d = 0.94). Blinded evaluation revealed residents’ Hard-case mean correctness rose from 0.589 to 0.734 (+0.145); difficulty-standardised completely-correct rates confirmed a medium effect (Δ = 0.092; P = .07; d = 0.47). Automated and blinded manual assessment showed only modest agreement (Cohen's κ = 0.148), with 45% of clinically correct diagnoses receiving no automated credit; reported F1 improvements are therefore conservative estimates. Cross-expertise concordance increased significantly (Δ = 0.142; P < .001; d = 1.48). Dialogue analysis revealed expertise-dependent strategies: seniors employed targeted, hypothesis-driven queries while residents used broader exploratory questioning. CONCLUSIONS Interactive LLM assistance meaningfully enhances diagnostic accuracy, particularly for resident physicians on complex cases. The expertise-stratified benefit profile, large effect sizes, and significant convergence in cross-expertise concordance suggest that adaptive LLM deployment, targeting high-complexity cases and less experienced clinicians, is a promising and evidence-grounded strategy for emergency diagnostic support.
- 12 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessHuman–LLM Dialogue Improves Diagnostic Accuracy in Emergency Care: Controlled Crossover Study (Preprint)
BACKGROUND Clinical decision-making in emergency medicine requires rapid, accurate diagnoses under uncertainty. Large language models (LLMs) have shown diagnostic potential, but evidence for their benefit in real physician workflows remains limited. OBJECTIVE This study evaluated whether MedSyn, a physician–LLM dialogue system, improves diagnostic accuracy in live emergency care workflows, and examined how benefit varies with case difficulty and physician expertise. METHODS Seven physicians (three senior internists, four residents) completed unassisted (baseline) and AI-assisted (interactive) sessions across 52 MIMIC-IV cases stratified by difficulty (Easy, Medium, Hard). Diagnostic performance was measured using automated fuzzy-matching metrics (any-match accuracy, exact-match accuracy, diagnosis-set F1) and blinded expert evaluation. Between-condition comparisons used paired bootstrap resampling (20,000 replicates, seed 42). RESULTS Interactive support significantly improved overall diagnostic accuracy: difficulty-standardised any-match accuracy improved by 0.156 (P < .001; d = 1.25). Residents showed the largest gains, with F1 improving by 0.138 (P < .001; d = 0.94). Blinded evaluation revealed residents’ Hard-case mean correctness rose from 0.589 to 0.734 (+0.145); difficulty-standardised completely-correct rates confirmed a medium effect (Δ = 0.092; P = .07; d = 0.47). Automated and blinded manual assessment showed only modest agreement (Cohen's κ = 0.148), with 45% of clinically correct diagnoses receiving no automated credit; reported F1 improvements are therefore conservative estimates. Cross-expertise concordance increased significantly (Δ = 0.142; P < .001; d = 1.48). Dialogue analysis revealed expertise-dependent strategies: seniors employed targeted, hypothesis-driven queries while residents used broader exploratory questioning. CONCLUSIONS Interactive LLM assistance meaningfully enhances diagnostic accuracy, particularly for resident physicians on complex cases. The expertise-stratified benefit profile, large effect sizes, and significant convergence in cross-expertise concordance suggest that adaptive LLM deployment, targeting high-complexity cases and less experienced clinicians, is a promising and evidence-grounded strategy for emergency diagnostic support.
- Open Access
- 1 January 2025
- Published by Wiley in Emergency Medicine International
- Vol. 2025 (1) , 2807776
Implementation of Revised Simplified Geneva Score in Triage Nurse Evaluation for Patients With Suspected Pulmonary Embolism: A Retrospective Chart Review
Background: Pulmonary embolism (PE) is a clinical condition frequently encountered in the emergency department (ED), with a high and early mortality rate. ED triage determines the priority of further evaluation of care at the time of patient arrival. Very little is known about the specific role of ED triage in PE. We aimed to evaluate (1) whether the current five‐level triage (5LT) system can identify patients with PE and differently prioritize them for medical evaluation and (2) the discriminatory capacity of simplified revised Geneva score (SRGS) toward PE diagnosis when calculated by triage nurses. Methods: A retrospective chart review on ED patients who underwent computed tomography pulmonary angiography (CTPA) in 2023. Based on the CTPA report, patients were categorized into two subgroups: CTPA PE‐negative and CTPA PE‐positive. We then searched for correlations between PE diagnosis and triage priority level, time from triage to medical evaluation, SRGS, and National Early Warning Score 2 (NEWS2). Results: Of the 196 patients included in the analysis (age 71.1 ± 16.9), 45 (23.0%) were CTPA PE‐positive (26 proximal PE and 19 distal PE). There was no correlation between the assigned triage color code and the CTPA results. Although we found a statistically significant difference in the prevalence of CTPA‐confirmed PE according to the results of the SRGS ( p = 0.014), the SRGS calculated at the time of triage showed a poor prediction accuracy for subsequent PE diagnosis (area under curve [AUC] 0.608). NEWS2 was significantly associated with the triage‐assigned priority level ( p < 0.001). Conclusions: The current 5LT was unable to differently prioritize patients with or without PE, and it seems unlikely that implementation of SRGS in the triage nurse evaluation will significantly improve the prioritization of patients with suspected PE for medical evaluation. Nonetheless, application of SRGS in triage evaluation may improve the appropriateness of the subsequent clinical pathway for PE diagnosis and risk stratification.
- 1 January 2025
- Published by Wiley in Emergency Medicine International
- Vol. 2025 (1) , 2807776
Open AccessImplementation of Revised Simplified Geneva Score in Triage Nurse Evaluation for Patients With Suspected Pulmonary Embolism: A Retrospective Chart Review
Background: Pulmonary embolism (PE) is a clinical condition frequently encountered in the emergency department (ED), with a high and early mortality rate. ED triage determines the priority of further evaluation of care at the time of patient arrival. Very little is known about the specific role of ED triage in PE. We aimed to evaluate (1) whether the current five‐level triage (5LT) system can identify patients with PE and differently prioritize them for medical evaluation and (2) the discriminatory capacity of simplified revised Geneva score (SRGS) toward PE diagnosis when calculated by triage nurses. Methods: A retrospective chart review on ED patients who underwent computed tomography pulmonary angiography (CTPA) in 2023. Based on the CTPA report, patients were categorized into two subgroups: CTPA PE‐negative and CTPA PE‐positive. We then searched for correlations between PE diagnosis and triage priority level, time from triage to medical evaluation, SRGS, and National Early Warning Score 2 (NEWS2). Results: Of the 196 patients included in the analysis (age 71.1 ± 16.9), 45 (23.0%) were CTPA PE‐positive (26 proximal PE and 19 distal PE). There was no correlation between the assigned triage color code and the CTPA results. Although we found a statistically significant difference in the prevalence of CTPA‐confirmed PE according to the results of the SRGS ( p = 0.014), the SRGS calculated at the time of triage showed a poor prediction accuracy for subsequent PE diagnosis (area under curve [AUC] 0.608). NEWS2 was significantly associated with the triage‐assigned priority level ( p < 0.001). Conclusions: The current 5LT was unable to differently prioritize patients with or without PE, and it seems unlikely that implementation of SRGS in the triage nurse evaluation will significantly improve the prioritization of patients with suspected PE for medical evaluation. Nonetheless, application of SRGS in triage evaluation may improve the appropriateness of the subsequent clinical pathway for PE diagnosis and risk stratification.
- Open Access
- 15 September 2020
- Published by Springer Nature in Research Square
Recreational opium use as a risk factor for coronary artery disease: results from the premature coronary artery disease Milano-Iran (MIran) study
The spreading of recreational opium use pose new health related concerns. In some areas of Asia its use is believed to protect from cardiovascular disorders, such as coronary artery disease (CAD). However, whether opium use has an association with CAD is unclear. We aimed to investigate the association between opium use and CAD. We set up a case-control analysis, i.e., the premature CAD Milano-Iran (MIran) study by enrolling consecutive young patients who underwent a coronary angiography at the Tehran Heart Center, between 2009 and 2012. Incident cases with CAD were contrasted with controls for recreational opium use. Relative risks were calculated in terms of odds ratios (ORs) by logistic regression models adjusted for age, sex, cigarette smoking, body mass index, hypertension, hyperlipidaemia, and diabetes. Interaction analyses were performed between opium and major cardiovascular risk factors. 1011 patients with CAD (mean age 43.6 years) and 2002 controls (mean age 54.3 years) were included in the study. Habitual opium users had a 3.8-fold increased risk of CAD (95%CI 2.4–6.2) compared with non-users. The association was strongest for men, with a fully adjusted OR of 5.5 (95%CI 3.0-9.9). No interaction was observed for the combination of opium addiction and hypertension, or diabetes, but an excess in risk was found in opium users with hyperlipidaemia (OR 16.8, 95%CI 8.9–31.7, expected OR 12.2), suggesting supra-additive interaction. In conclusion, despite common beliefs, we showed that recreational opium use is associated with an increased risk of CAD, even when other cardiovascular risk factors are taken into account.
- 15 September 2020
- Published by Springer Nature in Research Square
Open AccessRecreational opium use as a risk factor for coronary artery disease: results from the premature coronary artery disease Milano-Iran (MIran) study
The spreading of recreational opium use pose new health related concerns. In some areas of Asia its use is believed to protect from cardiovascular disorders, such as coronary artery disease (CAD). However, whether opium use has an association with CAD is unclear. We aimed to investigate the association between opium use and CAD. We set up a case-control analysis, i.e., the premature CAD Milano-Iran (MIran) study by enrolling consecutive young patients who underwent a coronary angiography at the Tehran Heart Center, between 2009 and 2012. Incident cases with CAD were contrasted with controls for recreational opium use. Relative risks were calculated in terms of odds ratios (ORs) by logistic regression models adjusted for age, sex, cigarette smoking, body mass index, hypertension, hyperlipidaemia, and diabetes. Interaction analyses were performed between opium and major cardiovascular risk factors. 1011 patients with CAD (mean age 43.6 years) and 2002 controls (mean age 54.3 years) were included in the study. Habitual opium users had a 3.8-fold increased risk of CAD (95%CI 2.4–6.2) compared with non-users. The association was strongest for men, with a fully adjusted OR of 5.5 (95%CI 3.0-9.9). No interaction was observed for the combination of opium addiction and hypertension, or diabetes, but an excess in risk was found in opium users with hyperlipidaemia (OR 16.8, 95%CI 8.9–31.7, expected OR 12.2), suggesting supra-additive interaction. In conclusion, despite common beliefs, we showed that recreational opium use is associated with an increased risk of CAD, even when other cardiovascular risk factors are taken into account.
- Open Access
- 7 March 2019
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 19 (1) , 55
Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study
We aimed to investigate the role of hypercoagulability on the risk of lifetime cardiovascular recurrences after myocardial infarction or ischaemic stroke. Young women (< 50 years) with either myocardial infarction (n = 197) or ischaemic stroke (n = 107) were followed between 1995 and 2012 in the RATIO follow-up study. To determine whether hypercoagulability affects the risk or recurrence, a coagulation score based on acquired and inherited markers was compiled and used in a quartile analysis. Hazard ratios (HRs) obtained from Cox proportional models and adjusted for several cardiovascular risk factors were used to compare quartiles of the coagulation score for the risk of recurrence. During a median follow-up of 19 years, 59 cardiovascular recurrences occurred. In patients with myocardial infarction no association was found between a high prothrombotic score and recurrences (highest quartile vs lowest quartile HR 0.7, 95% CI, 0.3–1.8). Conversely, ischaemic stroke patients with a high prothrombotic score showed a doubling in risk of long-term cardiovascular recurrences (HR 1.9, 95% CI 0.6–6.3) compared with ischaemic stroke patients and low levels of the score, with a dose response relationship. An increased coagulation tendency might be associated with long-term cardiovascular risk in women with ischaemic stroke, but not in women with myocardial infarction.
- 7 March 2019
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 19 (1) , 55
Open AccessHypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study
We aimed to investigate the role of hypercoagulability on the risk of lifetime cardiovascular recurrences after myocardial infarction or ischaemic stroke. Young women (< 50 years) with either myocardial infarction (n = 197) or ischaemic stroke (n = 107) were followed between 1995 and 2012 in the RATIO follow-up study. To determine whether hypercoagulability affects the risk or recurrence, a coagulation score based on acquired and inherited markers was compiled and used in a quartile analysis. Hazard ratios (HRs) obtained from Cox proportional models and adjusted for several cardiovascular risk factors were used to compare quartiles of the coagulation score for the risk of recurrence. During a median follow-up of 19 years, 59 cardiovascular recurrences occurred. In patients with myocardial infarction no association was found between a high prothrombotic score and recurrences (highest quartile vs lowest quartile HR 0.7, 95% CI, 0.3–1.8). Conversely, ischaemic stroke patients with a high prothrombotic score showed a doubling in risk of long-term cardiovascular recurrences (HR 1.9, 95% CI 0.6–6.3) compared with ischaemic stroke patients and low levels of the score, with a dose response relationship. An increased coagulation tendency might be associated with long-term cardiovascular risk in women with ischaemic stroke, but not in women with myocardial infarction.
- Open Access
- 18 June 2018
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 45 (01) , 036-042
Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome
An increased von Willebrand factor propeptide (VWFpp) to VWF antigen (VWF:Ag) ratio (VWFpp/VWF:Ag) indicates an enhanced clearance of VWF. This finding has been described in von Willebrand disease (VWD) and in acquired von Willebrand syndrome (AVWS). A distinction between these two diseases, one congenital and the other acquired, is primarily based on family and personal history of bleeding. However, if this information is scanty, the diagnosis might be challenging due to the lack of an effective diagnostic biomarker. In this cross-sectional study, we assessed the ability of VWFpp/VWF:Ag for the differential diagnosis between VWD and AVWS. VWFpp/VWF:Ag was measured in a group of 153 patients (125 with VWD and 28 with AVWS). Most patients with AVWS and VWD showed an increased VWFpp/VWF:Ag, although to variable degrees. A marked increase of VWFpp/VWF:Ag was mainly associated with the diagnosis of AVWS and VWD type 1 Vicenza. A receiver operating characteristic curve was used to identify the optimal cutoff of VWFpp/VWF:Ag for discrimination of patients with a modestly increased (most VWD cases) versus those with a markedly increased clearance (AVWS and VWD type 1 Vicenza), and this cutoff was identified at the value of 3.9 (sensitivity: 0.70, specificity: 0.97). The ROC curve sorting from a logistic model containing VWFpp/VWF:Ag, age, and sex had an area under the curve (AUC) of 0.88 (95% confidence interval: 0.80–0.95). A subsequent molecular evaluation discriminated VWD type 1 Vicenza from AVWS. In conclusion, VWFpp/VWF:Ag appears helpful to discriminate patients with a markedly increase VWF clearance (AVWS or VWD type 1 Vicenza) from those with a modestly increased clearance (most VWD patients).
- 18 June 2018
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 45 (01) , 036-042
Open AccessEvaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome
An increased von Willebrand factor propeptide (VWFpp) to VWF antigen (VWF:Ag) ratio (VWFpp/VWF:Ag) indicates an enhanced clearance of VWF. This finding has been described in von Willebrand disease (VWD) and in acquired von Willebrand syndrome (AVWS). A distinction between these two diseases, one congenital and the other acquired, is primarily based on family and personal history of bleeding. However, if this information is scanty, the diagnosis might be challenging due to the lack of an effective diagnostic biomarker. In this cross-sectional study, we assessed the ability of VWFpp/VWF:Ag for the differential diagnosis between VWD and AVWS. VWFpp/VWF:Ag was measured in a group of 153 patients (125 with VWD and 28 with AVWS). Most patients with AVWS and VWD showed an increased VWFpp/VWF:Ag, although to variable degrees. A marked increase of VWFpp/VWF:Ag was mainly associated with the diagnosis of AVWS and VWD type 1 Vicenza. A receiver operating characteristic curve was used to identify the optimal cutoff of VWFpp/VWF:Ag for discrimination of patients with a modestly increased (most VWD cases) versus those with a markedly increased clearance (AVWS and VWD type 1 Vicenza), and this cutoff was identified at the value of 3.9 (sensitivity: 0.70, specificity: 0.97). The ROC curve sorting from a logistic model containing VWFpp/VWF:Ag, age, and sex had an area under the curve (AUC) of 0.88 (95% confidence interval: 0.80–0.95). A subsequent molecular evaluation discriminated VWD type 1 Vicenza from AVWS. In conclusion, VWFpp/VWF:Ag appears helpful to discriminate patients with a markedly increase VWF clearance (AVWS or VWD type 1 Vicenza) from those with a modestly increased clearance (most VWD patients).
- Open Access
- 26 October 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0186699
Thrombosis after liver transplantation for hepatocellular carcinoma
The influence of thrombosis on the prognosis of patients with hepatocellular carcinoma (HCC) after liver transplantation (LT) and the role of the commonest inherited thrombophilia abnormalities factor V Leiden and prothrombin G20210A in the development of thrombosis are unknown. We investigated a cohort of patients who underwent LT for HCC with the aim to estimate the incidence rate (IR) of thrombosis, its influence on mortality and re-transplantation rates and, in the frame of a nested case-control study, the role of thrombophilia in donors and recipients for the development of thrombosis. Four-hundred and thirty patients underwent LT and were followed for a median of 7.2 years. Twenty-six recipients (6%) developed thrombosis (IR 1.06 [95%CI: 0.71–1.53] per 100 pts-yr). Mortality rate after LT was 3.95 (95%CI: 3.22–4.79) per 100 pts-yr and was not influenced by thrombosis. Re-transplantation was planned for 33 patients and was more common in patients with thrombosis than in those without (HR 2.50 [95%CI: 0.87–7.17]). The risk of thrombosis was 4 times higher in recipients with thrombophilia than in those without (OR 4.23 [95%CI: 0.99–18.04]) and 6 times higher when the analysis was restricted to venous thrombosis (OR 6.26 [95%CI: 1.19–32.85]). The presence of inherited thrombophilia in the donors did not increase the risk of thrombosis of the recipient. In conclusion, thrombosis is a complication of 6% of patients transplanted for HCC and increases the risk of re-transplantation but not of mortality. The risk of thrombosis, particularly venous, is increased in the presence of thrombophilia abnormalities in the recipients.
- 26 October 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0186699
Open AccessThrombosis after liver transplantation for hepatocellular carcinoma
The influence of thrombosis on the prognosis of patients with hepatocellular carcinoma (HCC) after liver transplantation (LT) and the role of the commonest inherited thrombophilia abnormalities factor V Leiden and prothrombin G20210A in the development of thrombosis are unknown. We investigated a cohort of patients who underwent LT for HCC with the aim to estimate the incidence rate (IR) of thrombosis, its influence on mortality and re-transplantation rates and, in the frame of a nested case-control study, the role of thrombophilia in donors and recipients for the development of thrombosis. Four-hundred and thirty patients underwent LT and were followed for a median of 7.2 years. Twenty-six recipients (6%) developed thrombosis (IR 1.06 [95%CI: 0.71–1.53] per 100 pts-yr). Mortality rate after LT was 3.95 (95%CI: 3.22–4.79) per 100 pts-yr and was not influenced by thrombosis. Re-transplantation was planned for 33 patients and was more common in patients with thrombosis than in those without (HR 2.50 [95%CI: 0.87–7.17]). The risk of thrombosis was 4 times higher in recipients with thrombophilia than in those without (OR 4.23 [95%CI: 0.99–18.04]) and 6 times higher when the analysis was restricted to venous thrombosis (OR 6.26 [95%CI: 1.19–32.85]). The presence of inherited thrombophilia in the donors did not increase the risk of thrombosis of the recipient. In conclusion, thrombosis is a complication of 6% of patients transplanted for HCC and increases the risk of re-transplantation but not of mortality. The risk of thrombosis, particularly venous, is increased in the presence of thrombophilia abnormalities in the recipients.
- Top Cited Papers
- 1 September 2017
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 2 (3) , 195-221
European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – Endorsed by the European Academy of Neurology
The current proposal for cerebral venous thrombosis guideline followed the Grading of Recommendations, Assessment, Development, and Evaluation system, formulating relevant diagnostic and treatment questions, performing systematic reviews of all available evidence and writing recommendations and deciding on their strength on an explicit and transparent manner, based on the quality of available scientific evidence. The guideline addresses both diagnostic and therapeutic topics. We suggest using magnetic resonance or computed tomography angiography for confirming the diagnosis of cerebral venous thrombosis and not screening patients with cerebral venous thrombosis routinely for thrombophilia or cancer. We recommend parenteral anticoagulation in acute cerebral venous thrombosis and decompressive surgery to prevent death due to brain herniation. We suggest to use preferentially low-molecular weight heparin in the acute phase and not using direct oral anticoagulants. We suggest not using steroids and acetazolamide to reduce death or dependency. We suggest using antiepileptics in patients with an early seizure and supratentorial lesions to prevent further early seizures. We could not make recommendations due to very poor quality of evidence concerning duration of anticoagulation after the acute phase, thrombolysis and/or thrombectomy, therapeutic lumbar puncture, and prevention of remote seizures with antiepileptic drugs. We suggest that in women who suffered a previous cerebral venous thrombosis, contraceptives containing oestrogens should be avoided. We suggest that subsequent pregnancies are safe, but use of prophylactic low-molecular weight heparin should be considered throughout pregnancy and puerperium. Multicentre observational and experimental studies are needed to increase the level of evidence supporting recommendations on the diagnosis and management of cerebral venous thrombosis.
- 1 September 2017
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 2 (3) , 195-221
Top Cited PapersEuropean Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – Endorsed by the European Academy of Neurology
The current proposal for cerebral venous thrombosis guideline followed the Grading of Recommendations, Assessment, Development, and Evaluation system, formulating relevant diagnostic and treatment questions, performing systematic reviews of all available evidence and writing recommendations and deciding on their strength on an explicit and transparent manner, based on the quality of available scientific evidence. The guideline addresses both diagnostic and therapeutic topics. We suggest using magnetic resonance or computed tomography angiography for confirming the diagnosis of cerebral venous thrombosis and not screening patients with cerebral venous thrombosis routinely for thrombophilia or cancer. We recommend parenteral anticoagulation in acute cerebral venous thrombosis and decompressive surgery to prevent death due to brain herniation. We suggest to use preferentially low-molecular weight heparin in the acute phase and not using direct oral anticoagulants. We suggest not using steroids and acetazolamide to reduce death or dependency. We suggest using antiepileptics in patients with an early seizure and supratentorial lesions to prevent further early seizures. We could not make recommendations due to very poor quality of evidence concerning duration of anticoagulation after the acute phase, thrombolysis and/or thrombectomy, therapeutic lumbar puncture, and prevention of remote seizures with antiepileptic drugs. We suggest that in women who suffered a previous cerebral venous thrombosis, contraceptives containing oestrogens should be avoided. We suggest that subsequent pregnancies are safe, but use of prophylactic low-molecular weight heparin should be considered throughout pregnancy and puerperium. Multicentre observational and experimental studies are needed to increase the level of evidence supporting recommendations on the diagnosis and management of cerebral venous thrombosis.
- Top Cited PapersOpen Access
- 20 August 2017
- Published by Wiley in European Journal of Neurology
- Vol. 24 (10) , 1203-1213
European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology
Background and purpose: Current guidelines on cerebral venous thrombosis (CVT) diagnosis and management were issued by the European Federation of Neurological Societies in 2010. We aimed to update the previous European Federation of Neurological Societies guidelines using a clearer and evidence‐based methodology.Method: We followed the Grading of Recommendations, Assessment, Development and Evaluation system, formulating relevant diagnostic and treatment questions, performing systematic reviews and writing recommendations based on the quality of available scientific evidence.Results: We suggest using magnetic resonance or computed tomographic angiography for confirming the diagnosis of CVT and not routinely screening patients with CVT for thrombophilia or cancer. We recommend parenteral anticoagulation in acute CVT and decompressive surgery to prevent death due to brain herniation. We suggest preferentially using low‐molecular‐weight heparin in the acute phase and not direct oral anticoagulants. We suggest not using steroids and acetazolamide to reduce death or dependency. We suggest using antiepileptics in patients with an early seizure and supratentorial lesions to prevent further early seizures. We could not make recommendations concerning duration of anticoagulation after the acute phase, thrombolysis and/or thrombectomy, therapeutic lumbar puncture, and prevention of remote seizures with antiepileptic drugs. We suggest that, in women who have suffered a previous CVT, contraceptives containing oestrogens should be avoided. We suggest that subsequent pregnancies are safe, but use of prophylactic low‐molecular‐weight heparin should be considered throughout pregnancy and puerperium.Conclusions: Multicentre observational and experimental studies are needed to increase the level of evidence supporting recommendations on the diagnosis and management of CVT.
- 20 August 2017
- Published by Wiley in European Journal of Neurology
- Vol. 24 (10) , 1203-1213
Top Cited PapersOpen AccessEuropean Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology
Background and purpose: Current guidelines on cerebral venous thrombosis (CVT) diagnosis and management were issued by the European Federation of Neurological Societies in 2010. We aimed to update the previous European Federation of Neurological Societies guidelines using a clearer and evidence‐based methodology.Method: We followed the Grading of Recommendations, Assessment, Development and Evaluation system, formulating relevant diagnostic and treatment questions, performing systematic reviews and writing recommendations based on the quality of available scientific evidence.Results: We suggest using magnetic resonance or computed tomographic angiography for confirming the diagnosis of CVT and not routinely screening patients with CVT for thrombophilia or cancer. We recommend parenteral anticoagulation in acute CVT and decompressive surgery to prevent death due to brain herniation. We suggest preferentially using low‐molecular‐weight heparin in the acute phase and not direct oral anticoagulants. We suggest not using steroids and acetazolamide to reduce death or dependency. We suggest using antiepileptics in patients with an early seizure and supratentorial lesions to prevent further early seizures. We could not make recommendations concerning duration of anticoagulation after the acute phase, thrombolysis and/or thrombectomy, therapeutic lumbar puncture, and prevention of remote seizures with antiepileptic drugs. We suggest that, in women who have suffered a previous CVT, contraceptives containing oestrogens should be avoided. We suggest that subsequent pregnancies are safe, but use of prophylactic low‐molecular‐weight heparin should be considered throughout pregnancy and puerperium.Conclusions: Multicentre observational and experimental studies are needed to increase the level of evidence supporting recommendations on the diagnosis and management of CVT.
- 1 March 2017
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 38, 46-51
Red cell distribution width and the risk of cerebral vein thrombosis: A case–control study
- 1 March 2017
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 38, 46-51
Red cell distribution width and the risk of cerebral vein thrombosis: A case–control study
- 1 December 2016
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 14 (12) , 2386-2393
Pregnancy outcome after a first episode of cerebral vein thrombosis
- 1 December 2016
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 14 (12) , 2386-2393
Pregnancy outcome after a first episode of cerebral vein thrombosis